|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Antisoma plc, of London, completed recruitment in a Phase I trial of its radiolabeled monoclonal antibody fragment, TheraFab. The trial, which enrolled patients with non-small-cell lung cancer, is designed to show how effectively TheraFab binds to lung-derived tumor cells and to check that the antibody does not deliver unacceptable levels of radiation to healthy tissues. TheraFab is a member of the HMFG-1 family of antibody products, which bind to the tumor antigen MUC1, known to be expressed in a high proportion of non-small-cell lung cancers, the company said.
BioMarin Pharmaceutical Inc., of Novato, Calif., completed its acquisition of all outstanding shares ...